Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,843 across all filing types
Latest filing 2015-04-26 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
前次募集资金使用情况鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled '前次募集资金使用情况 鉴证报告' which translates to 'Verification Report on the Use of Previous Fundraising Proceeds'. It is issued by an accounting firm and includes an attestation on the use of funds raised previously by the company. The document references compliance with regulations from the China Securities Regulatory Commission regarding fundraising use reports. The content is a standalone audit or verification report on the use of capital raised, not a full annual or interim financial report. It does not contain comprehensive financial statements or management discussion but focuses on the audit/verification of fundraising use. Therefore, it fits the category of Audit Report / Information (AR). The document length is short (1296 characters), but it contains the actual verification report, not just an announcement or certification letter. Hence, it is not RPA or RNS. FY 2014
2015-04-26 Chinese
独立董事关于公司非公开发行股票及本次发行涉及重大关联交易之独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion statement from the independent directors of 普洛药业股份有限公司 regarding a non-public issuance of shares and related significant connected transactions. It references compliance with relevant laws and regulations, and expresses agreement with the proposed issuance and related transactions. The document is a formal opinion letter rather than a full report or announcement of results. It does not contain financial statements or detailed financial data, nor is it a brief announcement or a proxy solicitation. It is a governance-related document expressing independent directors' opinions on a capital raising transaction and related connected party dealings. Therefore, it fits best under the category of Board/Management Information (MANG), which includes announcements related to board decisions and management opinions on corporate actions.
2015-04-26 Chinese
内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled '内部控制审计报告' which translates to 'Internal Control Audit Report'. It references auditing standards and the responsibility of the company's board and auditors regarding internal control over financial reporting as of December 31, 2014. The document is issued by an accounting firm and contains an audit opinion on the effectiveness of internal controls. The length is about 1060 characters, which is relatively short but contains substantive audit content rather than just an announcement. This matches the definition of an Audit Report / Information (AR), which includes standalone audit reports and results of internal control audits, distinct from full annual reports or other filings. Therefore, the correct classification is AR with high confidence. FY 2014
2015-04-26 Chinese
2015年度非公开发行A股股票募集资金运用的可行性分析报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2015年度非公开发行A股股票募集资金运用的可行性分析报告" which translates to "2015 Non-public Issuance of A Shares Fundraising Feasibility Analysis Report". It details the use of funds raised from a non-public stock issuance, including investment projects, capital structure impact, financial condition, and business impact. The content focuses on the company's capital raising activities, the planned use of proceeds, and the financial and operational effects of the fundraising. There are no financial statements or quarterly/yearly financial results presented, nor is it an announcement of a report publication or voting results. The document is a detailed update on the company's capital raising and financing activities. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (7658 characters) supports it being a full report rather than a brief announcement.
2015-04-26 Chinese
复牌公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement from 普洛药业股份有限公司 regarding the resumption of trading of its stock after a suspension period related to a non-public share issuance plan. It references previous suspension announcements and the approval of a share issuance plan by the board. The document is short (689 characters) and serves as a notice about the stock resumption, not a detailed financial report or presentation. It fits the category of Capital/Financing Update (CAP) because it relates to fundraising activities and capital structure changes, specifically the non-public issuance of shares and the resumption of trading after suspension for this purpose.
2015-04-26 Chinese
西南证券股份有限公司关于公司非公开发行股份购买资产并募集配套资金暨关联交易之2014年度业绩承诺实现情况专项审核意见
Audit Report / Information Classification · 95% confidence The document is a specialized audit opinion report issued by Southwest Securities Co., Ltd. regarding the 2014 performance commitment fulfillment related to a non-public share issuance and asset purchase transaction by Puluo Pharmaceutical Co., Ltd. It includes detailed financial data, profit forecasts, compensation commitments, and verification results by an accounting firm. The document is focused on verifying the achievement of profit commitments tied to a major asset restructuring transaction and includes substantive financial analysis and audit conclusions. It is not a full annual report (10-K), nor a simple announcement or certification. It is a standalone audit report related to a specific transaction and performance commitment, fitting the definition of an Audit Report / Information (AR). The document length (4548 characters) and content confirm it is the report itself, not just an announcement or certification. Therefore, the correct classification is AR with high confidence. FY 2014
2015-04-23 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.